Skip to main content

Market Overview

Abbott's Navitor Aortic Heart Valve Replacement Scores European Approval

Share:
Abbott's Navitor Aortic Heart Valve Replacement Scores European Approval
  • Abbott Laboratories’ (NYSE: ABT) Navitor transcatheter aortic valve implantation (TAVI) system has received a CE mark, making it available in Europe to those with severe aortic stenosis and a high or extreme risk of complications from surgery.
  • TAVR systems offer a less risky, minimally invasive alternative to open-heart surgery to treat aortic stenosis, where the aortic valve narrows and restricts blood flow out of the left ventricle to the aorta, weakening the heart muscle.
  • The Navitor valve is implanted using Abbott’s FlexNav device, which received its CE mark last year. The catheter is designed to improve the flexibility and stability of other TAVR delivery devices and can be used in patients with aorta diameters as small as 5 millimeters.
  • In the U.S., the Navitor system and FlexNav delivery device are only available for investigative use.
  • Price Action: ABT shares closed 1.33% lower at $116.74 on Monday.
 

Related Articles (ABT)

View Comments and Join the Discussion!

Posted-In: BriefsNews Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com